Dateline City:
KENILWORTH, N.J.
Company Initiates Pivotal Phase 3 Studies Evaluating Relebactam in Combination with Imipenem/Cilastatin for Treatment of Serious Bacterial Infections
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that a Phase 2 study of relebactam, the companys
investigational beta-lactamase inhibitor for the treatment, in
combination with imipenem/cilastatin (an approved carbapenem
antibiotic), of complicated intra-abdominal infections, met its primary
endpoint, and that Merck is now initiating pivotal Phase 3 studies.
Language:
English
Contact:
MerckMedia:Doris Li, (908) 246-5701Ian McConnell, (973) 901-5722orInvestor:Teri Loxam, (908) 740-1986Justin Holko, (908) 740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more